Reported relationships
Latest disclosed role at each company.
No relationships currently tracked through insider filings.
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
No balances currently tracked through insider filings.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
COLLEGIUM PHARMACEUTICAL, INC
Report date March 04, 2025 · Filed March 06, 2025
Section 16 reporting ended · disclosed 2025-03-06. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 108,137 |
Ending reported balance
After 2025-03-06 transaction · row 4
4 source rows · reconciled sequenceRow 1 · 2025-03-04 · Exercise / conversion · Acquired 40,000 · Balance 194,204 Row 2 · 2025-03-04 · Sale · Disposed 40,000 · Balance 154,204 F1: The price reported in column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $28.00 to $28.24, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the U.S. Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (1), (2) and (3) to this Form 4. Row 3 · 2025-03-05 · Sale · Disposed 20,000 · Balance 134,204 F2: The price reported in column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $28.00 to $28.18, inclusive. Row 4 · 2025-03-06 · Sale · Disposed 26,067 · Balance 108,137 F3: The price reported in column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $28.50 to $28.58, inclusive. |
| Stock Option (Right to Purchase)SEC Table II · derivative / convertible security · Conversion / exercise price $24.03 · Expires 2028-04-04 | Direct | 0 |
Reported balance
After 2025-03-04 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2025-03-04 · Exercise / conversion · Disposed 40,000 · Balance 0 F4: The option is fully vested and exercisable. |
Filing footnotes · ownership attribution and instrument terms
F1: The price reported in column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $28.00 to $28.24, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the U.S. Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (1), (2) and (3) to this Form 4.
F2: The price reported in column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $28.00 to $28.18, inclusive.
F3: The price reported in column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $28.50 to $28.58, inclusive.
F4: The option is fully vested and exercisable.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| January 19, 2021 Filed Jan 22, 2021 16:05 UTC Amendment | COLLEGIUM PHARMACEUTICAL, INC COLL · Entity 5169 | GrantCommon Stock | 45,360 | $0.00 | $0.00 |
DisclosureSEC source: 0001192482-21-000094 · edgar.xml · nonDerivative · entry 1 Kuhlmann Shirley R. · CIK 0001734919 · EVP and General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 102,891 F1 · shares: Reflects the grant of restricted stock units. Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock. Twenty-five percent (25%) of the restricted stock units vest on February 10, 2022, and the balance of the restricted stock units vest in equal annual installments over the following three-year period, subject to the reporting person's continued service with the issuer. The restricted stock units will be settled on each applicable vesting date in shares of the issuer's common stock. Read SEC document |
| October 15, 2020 Filed Oct 16, 2020 16:07 UTC | COLLEGIUM PHARMACEUTICAL, INC COLL · Entity 5169 | SaleCommon Stock | 7,060 | $20.82 | $146,989.20 |
DisclosureSEC source: 0001192482-20-000777 · edgar.xml · nonDerivative · entry 1 Kuhlmann Shirley R. · CIK 0001734919 · EVP and General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 57,531 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 18, 2020 and modified on September 15, 2020. Read SEC document |
| September 16, 2020 Filed Sep 18, 2020 16:17 UTC | COLLEGIUM PHARMACEUTICAL, INC COLL · Entity 5169 | Tax withholdingCommon Stock | 734 | $19.33 | $14,188.22 |
DisclosureSEC source: 0001192482-20-000703 · edgar.xml · nonDerivative · entry 1 Kuhlmann Shirley R. · CIK 0001734919 · EVP and General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 64,591 F1 · shares: Shares withheld by the Issuer to satisfy applicable withholding taxes upon vesting of restricted stock units. Read SEC document |
| March 16, 2020 Filed Mar 18, 2020 16:16 UTC | COLLEGIUM PHARMACEUTICAL, INC COLL · Entity 5169 | Tax withholdingCommon Stock | 734 | $15.41 | $11,310.94 |
DisclosureSEC source: 0001192482-20-000240 · edgar.xml · nonDerivative · entry 1 Kuhlmann Shirley R. · CIK 0001734919 · EVP and General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 65,325 F1 · shares: Shares withheld by the Issuer to satisfy applicable withholding taxes upon vesting of restricted stock units. Read SEC document |
| February 10, 2020 Filed Feb 12, 2020 16:25 UTC | COLLEGIUM PHARMACEUTICAL, INC COLL · Entity 5169 | Tax withholdingCommon Stock | 2,085 | $21.62 | $45,077.70 |
DisclosureSEC source: 0001192482-20-000149 · edgar.xml · nonDerivative · entry 1 Kuhlmann Shirley R. · CIK 0001734919 · EVP and General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 66,059 F1 · shares: Shares withheld by the Issuer to satisfy applicable withholding taxes upon vesting of restricted stock units. Read SEC document |
| February 05, 2020 Filed Feb 7, 2020 16:11 UTC | COLLEGIUM PHARMACEUTICAL, INC COLL · Entity 5169 | GrantStock Option (Right to Purchase) · Derivative | 27,500 | $0.00 Strike: $21.34 | $0.00 |
DisclosureSEC source: 0001192482-20-000138 · edgar.xml · derivative · entry 2 Kuhlmann Shirley R. · CIK 0001734919 · EVP and General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,500 Underlying: Common Stock · 27,500 shares Expires 2030-02-05 F2 · derivative.exercise_date: Twenty-five percent (25%) of the option vests and becomes exercisable on February 10, 2021, and the balance vests in equal quarterly installments (rounded up to the nearest whole share of common stock) over the following three-year period, subject to the reporting person's continued service with the issuer. Read SEC document |
| February 05, 2020 Filed Feb 7, 2020 16:11 UTC | COLLEGIUM PHARMACEUTICAL, INC COLL · Entity 5169 | GrantCommon Stock | 24,750 | $0.00 | $0.00 |
DisclosureSEC source: 0001192482-20-000138 · edgar.xml · nonDerivative · entry 1 Kuhlmann Shirley R. · CIK 0001734919 · EVP and General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 68,144 F1 · security: Reflects the grant of restricted stock units. Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock. Twenty-five percent (25%) of the restricted stock units vest on February 10, 2021, and the balance of the restricted stock units vest in equal annual installments over the following three-year period, subject to the reporting person's continued service with the issuer. The restricted stock units will be settled on each applicable vesting date in shares of the issuer's common stock. Read SEC document |
| September 16, 2019 Filed Sep 18, 2019 16:06 UTC | COLLEGIUM PHARMACEUTICAL, INC COLL · Entity 5169 | Tax withholdingCommon Stock | 736 | $12.44 | $9,155.84 |
DisclosureSEC source: 0001192482-19-000360 · edgar.xml · nonDerivative · entry 1 Kuhlmann Shirley R. · CIK 0001734919 · EVP and General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 43,394 F1 · shares: Shares withheld by the Issuer to satisfy applicable withholding taxes upon vesting of restricted stock units. Read SEC document |
| March 15, 2019 Filed Mar 19, 2019 17:41 UTC | COLLEGIUM PHARMACEUTICAL, INC COLL · Entity 5169 | Tax withholdingCommon Stock | 1,470 | $16.98 | $24,960.60 |
DisclosureSEC source: 0001192482-19-000167 · edgar.xml · nonDerivative · entry 1 Kuhlmann Shirley R. · CIK 0001734919 · EVP and General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 44,130 F1 · shares: Shares withheld by the Issuer to satisfy applicable withholding taxes upon vesting of restricted stock units. Read SEC document |
| January 25, 2019 Filed Jan 29, 2019 16:37 UTC | COLLEGIUM PHARMACEUTICAL, INC COLL · Entity 5169 | GrantStock Option (Right to Purchase) · Derivative | 25,600 | $0.00 Strike: $15.90 | $0.00 |
DisclosureSEC source: 0001192482-19-000055 · edgar.xml · derivative · entry 2 Kuhlmann Shirley R. · CIK 0001734919 · EVP and General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,600 Underlying: Common Stock · 25,600 shares Expires 2029-01-25 F2 · derivative.exercise_date: Twenty-five percent (25%) of the option vests and becomes exercisable on February 10, 2020, and the balance vests in equal quarterly installments (rounded up to the nearest whole share of common stock) over the following three-year period, subject to the reporting person's continued service with the issuer. Read SEC document |
| January 25, 2019 Filed Jan 29, 2019 16:37 UTC | COLLEGIUM PHARMACEUTICAL, INC COLL · Entity 5169 | GrantCommon Stock | 25,600 | $0.00 | $0.00 |
DisclosureSEC source: 0001192482-19-000055 · edgar.xml · nonDerivative · entry 1 Kuhlmann Shirley R. · CIK 0001734919 · EVP and General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 45,600 F1 · security: Reflects the grant of restricted stock units. Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock. Twenty-five percent (25%) of the restricted stock units vest on February 10, 2020, and the balance of the restricted stock units vest in equal annual installments over the following three-year period, subject to the reporting person's continued service with the issuer. The restricted stock units will be settled on each applicable vesting date in shares of the issuer's common stock. Read SEC document |
| April 04, 2018 Filed Apr 5, 2018 17:00 UTC | COLLEGIUM PHARMACEUTICAL, INC COLL · Entity 5169 | GrantStock Option (Right to Purchase) · Derivative | 40,000 | $0.00 Strike: $24.03 | $0.00 |
DisclosureSEC source: 0001192482-18-000154 · edgar.xml · derivative · entry 2 Kuhlmann Shirley R. · CIK 0001734919 · EVP and General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,000 Underlying: Common Stock · 40,000 shares Expires 2028-04-04 F2 · derivative.exercise_date: Twenty-five percent (25%) of the option vests and becomes exercisable on March 16, 2019, and the balance vests in equal monthly installments (rounded up to the nearest whole share of common stock) over the following three year period, subject to the reporting person's continued service with the issuer. Read SEC document |
| April 04, 2018 Filed Apr 5, 2018 17:00 UTC | COLLEGIUM PHARMACEUTICAL, INC COLL · Entity 5169 | GrantCommon Stock | 20,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001192482-18-000154 · edgar.xml · nonDerivative · entry 1 Kuhlmann Shirley R. · CIK 0001734919 · EVP and General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 F1 · security: Reflects the grant of restricted stock units. Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock. Twenty-five percent (25%) of the restricted stock units vest on March 16, 2019, and the balance of the restricted stock units vest in equal installments every six months (in each case, rounded up to the nearest whole share of common stock) over the following three year period, subject to the reporting person's continued service with the issuer. The restricted stock units will be settled on each applicable vesting date in shares of the issuer's common stock. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.